STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca Plc Stock Price, News & Analysis

AZN Nasdaq

Welcome to our dedicated page for Astrazeneca Plc news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca Plc stock.

AstraZeneca PLC (AZN) is a global biopharmaceutical leader focused on oncology, cardiovascular, respiratory, and immunology research. This centralized hub provides verified company announcements, press releases, and market-moving developments from authoritative sources.

Access real-time updates on clinical trial outcomes, regulatory approvals, and strategic collaborations that impact AZN's operational and financial positioning. Our curated selection includes earnings disclosures, product launch timelines, and research innovations critical for evaluating the company's healthcare sector influence.

Key coverage areas encompass quarterly financial results, acquisition activity, therapeutic pipeline advancements, and global health partnerships. All content adheres to journalistic standards and financial compliance requirements.

Bookmark this resource for streamlined tracking of AstraZeneca's material events. Updated continuously with primary-source information, it serves as an essential tool for monitoring AZN's contributions to pharmaceutical innovation.

News

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo reported groundbreaking results from the DESTINY-Breast09 Phase 3 trial, showing ENHERTU plus pertuzumab significantly outperformed standard therapy in first-line HER2+ metastatic breast cancer treatment. The combination reduced disease progression or death risk by 44% versus THP (taxane, trastuzumab, pertuzumab), achieving a median progression-free survival of 40.7 months compared to 26.9 months. The objective response rate was 85.1% for ENHERTU plus pertuzumab versus 78.6% for THP, with more complete responses (58 vs 33). The safety profile aligned with known data, though ILD/pneumonitis occurred in 12.1% of patients. This marks the first improvement in first-line treatment outcomes for broad HER2+ metastatic breast cancer patients in over a decade, potentially establishing a new standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
clinical trial
-
News

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo reported promising results for DATROWAY (datopotamab deruxtecan) in treating non-small cell lung cancer (NSCLC) across three clinical trials presented at ASCO 2025. In TROPION-Lung02, the combination of DATROWAY with pembrolizumab showed a 54.8% objective response rate in the doublet arm and 55.6% in the triplet arm including chemotherapy. TROPION-Lung04 demonstrated a 57.5% response rate when combining DATROWAY with rilvegostomig. The NeoCOAST-2 trial showed encouraging results in early-stage NSCLC with a 35.2% pathologic complete response rate when combining DATROWAY with durvalumab and chemotherapy. Safety profiles were consistent with previous studies, with manageable adverse events including some cases of interstitial lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Rhea-AI Summary
AstraZeneca's IMFINZI (durvalumab) in combination with FLOT chemotherapy demonstrated significant success in treating early-stage gastric and gastroesophageal junction cancers in the MATTERHORN Phase III trial. The perioperative treatment showed a 29% reduction in disease progression, recurrence, or death risk compared to chemotherapy alone. At two years, 67.4% of IMFINZI-treated patients remained event-free versus 58.5% in the comparator arm. The trial also showed a strong trend toward improved overall survival (HR=0.78). The IMFINZI-based regimen more than doubled the pathologic complete response rate (19% vs 7%). The safety profile was consistent with known profiles, with similar Grade 3 or higher adverse events between arms. This marks IMFINZI as the first and only immunotherapy to show statistically significant event-free survival in a global Phase III trial for this indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Rhea-AI Summary
AstraZeneca's SERENA-6 Phase III trial demonstrated significant success for camizestrant in treating HR-positive breast cancer. The drug, combined with CDK4/6 inhibitors, reduced disease progression or death risk by 56% compared to standard treatment, with median progression-free survival of 16.0 months versus 9.2 months. The trial marked the first use of circulating tumor DNA monitoring to detect and treat emerging resistance before disease progression. Camizestrant also improved quality of life metrics, delaying deterioration by 23.0 months compared to 6.4 months with standard treatment. The safety profile was consistent with known profiles, though Grade 3 adverse events were higher in the camizestrant arm (60% vs 46%). Based on these results, the FDA granted Breakthrough Therapy Designation for camizestrant in combination with CDK4/6 inhibitors for HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated superior efficacy in the DESTINY-Gastric04 phase 3 trial for second-line HER2-positive gastric cancer treatment. The drug showed a 30% reduction in death risk compared to ramucirumab plus paclitaxel, with median overall survival of 14.7 vs 11.4 months. ENHERTU achieved significant improvements across key metrics: 26% reduction in disease progression risk, 44.3% objective response rate (vs 29.1%), and 7.4 months median duration of response (vs 5.3 months). The safety profile remained consistent with previous trials, though interstitial lung disease occurred in 13.9% of ENHERTU patients, mostly low-grade. These results position ENHERTU as a potential global standard of care for second-line treatment in HER2-positive gastric cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Rhea-AI Summary

Danaher (NYSE: DHR) has announced a strategic partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize advanced diagnostic tools for precision medicine. The collaboration will leverage Danaher's Centers for Enabling Precision Medicine and technology from its subsidiary, Leica Biosystems, focusing initially on digital and computational pathology products with AI-assisted algorithms.

The partnership aims to create diagnostic tests that help identify patients most likely to benefit from targeted therapies. Leica Biosystems will utilize its global laboratory network to deploy these tests worldwide, supported by its commitment to open-access DICOM standards for enhanced workflow connectivity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
partnership
News

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

Rhea-AI Summary
AstraZeneca will present significant clinical trial data at the 2025 ASCO Annual Meeting (May 30-June 3), marking its seventh consecutive year with plenary presentations. The company will showcase over 80 abstracts featuring 20 medicines, including two plenary presentations. Key highlights include the SERENA-6 Phase III trial of camizestrant for HR-positive breast cancer, MATTERHORN Phase III trial of IMFINZI for gastric cancer, and DESTINY-Breast09 Phase III trial of ENHERTU for HER2-positive metastatic breast cancer. The SERENA-6 trial is notably the first positive Phase III trial for a next-generation oral SERD in first-line setting, while DESTINY-Breast09 is the first trial in over a decade showing superiority over first-line standard care in HER2-positive metastatic patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
News

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Rhea-AI Summary
AstraZeneca's AIRSUPRA demonstrated exceptional results in the Phase IIIb BATURA trial for mild asthma treatment. The study showed a 47% reduction in severe exacerbation risk compared to albuterol alone (5.1% vs 9.1%, p<0.001). The trial was stopped early due to overwhelming efficacy. Key findings include a 63% reduction in systemic corticosteroid exposure and consistent safety profile with albuterol. AIRSUPRA is the first FDA-approved anti-inflammatory rescue medication for as-needed treatment in asthma patients 18 and older. The results, published in the New England Journal of Medicine and presented at ATS 2025, support AIRSUPRA as a potential new standard of care, particularly significant for mild asthma patients who represent 50-70% of cases and account for up to 30% of asthma-related exacerbations and deaths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
-
News

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

Rhea-AI Summary
AstraZeneca (AZN) will present over 75 abstracts, including 8 late-breakers, at the American Thoracic Society (ATS) International Conference from May 16-21, 2025. The presentations focus on their respiratory portfolio targeting asthma, COPD, and other inflammatory diseases. Key highlights include:

- AIRSUPRA data showing potential as preferred rescue treatment across all asthma severities

- BREZTRI studies demonstrating impact on cardiopulmonary outcomes in COPD patients

- FASENRA research in EGPA treatment and eosinophilic inflammation

- TEZSPIRE data on severe asthma and chronic rhinosinusitis

- Early-stage pipeline developments including AI/machine learning applications in respiratory disease research

The company aims to transform respiratory care, addressing COPD as the third leading cause of death worldwide and targeting unmet needs in asthma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
News

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

Rhea-AI Summary
AstraZeneca's IMFINZI® (durvalumab) demonstrated significant success in a Phase III POTOMAC trial for treating high-risk non-muscle-invasive bladder cancer (NMIBC). The study showed that one year of IMFINZI treatment combined with standard BCG therapy significantly improved disease-free survival (DFS) compared to BCG therapy alone. This is particularly significant as over 70% of bladder cancer patients are diagnosed with NMIBC, and about half are classified as high-risk. Currently, 80% of patients experience disease recurrence, with almost half potentially requiring bladder removal surgery. The safety profile was consistent with known data, and the addition of IMFINZI did not compromise BCG therapy completion. However, a second experimental arm testing IMFINZI plus BCG induction-only therapy did not meet the DFS endpoint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
clinical trial

FAQ

What is the current stock price of Astrazeneca Plc (AZN)?

The current stock price of Astrazeneca Plc (AZN) is $94.01 as of January 8, 2026.

What is the market cap of Astrazeneca Plc (AZN)?

The market cap of Astrazeneca Plc (AZN) is approximately 295.0B.
Stock AZN logo
Astrazeneca Plc

Nasdaq:AZN

AZN Rankings

#37 Ranked by Market Cap
N/A Ranked by Dividends

AZN Stock Data

295.05B
3.10B
0%
16.74%
0.25%
Drug Manufacturers - General
Healthcare
Link
United Kingdom
Cambridge